- Home
- TDUP vs RLMD Comparison
TDUP vs RLMD Comparison
Compare TDUP & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDUP | RLMD |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 348.8M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TDUP | RLMD |
|---|---|---|
| Price | $1.58 | $4.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $2.80 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 1.8M | 1.6M |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.36 | 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $310,813,000.00 | $13,070.00 |
| Revenue This Year | $11.55 | N/A |
| Revenue Next Year | $10.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 19.53 | ★ 154.83 |
| 52 Week Low | $1.24 | $3.07 |
| 52 Week High | $8.76 | $8.00 |
Technical Indicators
Market Signals| Indicator | TDUP | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 59.22 |
| Support Level | N/A | $4.19 |
| Resistance Level | $2.52 | $4.53 |
| Average True Range (ATR) | 0.18 | 0.36 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 30.56 | 66.78 |
Price Performance
Historical ComparisonAbout TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for apparel, shoes, and accessories. The company's marketplaces have enabled buyers in the United States ("U.S.") to browse and purchase resale items principally for apparel, shoes, and accessories across a range of price points. The company's revenue is principally from the sale of secondhand apparel, shoes, and accessories on behalf of sellers.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.